Amgen Inc
AMGN294.390USD
Today
-4.98%
5 Days
-4.09%
1 Month
-7.37%
6 Months
-7.90%
Year to Date
+12.94%
1 Year
+9.05%
Agency Rating
Analyst Rating
Peer Comparison
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
News
Bernstein cuts Amgen PT on uncertainty over obesity drug candidate MariTide
** Bernstein cuts PT on drugmaker Amgen AMGN.O to $350 from $380, citing uncertainty over co's key obesity drug candidate MariTide** New PT is nearly a 19% upside to stock's last close** Brokerage says MariTide is a higher-risk-and-high-reward opportunity** Adds obesity pipeline is advancing...
Amgen profits rise, next MariTide studies start by mid-year
Feb 4 (Reuters) - Amgen AMGN.O posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
